Hypercholesterolemia Polygenic Risk Score

Two people can walk into a clinic with identical cholesterol numbers and walk out with very different futures. One had high LDL for decades before the test caught it. The other developed it recently. Your standard lipid panel cannot tell these stories apart, but your DNA can.

A hypercholesterolemia PRS (polygenic risk score) reads many small DNA variants you were born with and adds them up to estimate how strongly your genetics push your cholesterol higher across your entire life. It is a once-in-a-lifetime test that does not change with diet, age, or medications.

What This Score Actually Measures

Unlike a cholesterol blood test, which captures your level on one morning, a polygenic risk score captures your inherited tendency. It is calculated from many common gene variants that each slightly raise LDL (low-density lipoprotein) cholesterol. Individually these variants do little. Added together across dozens or hundreds of locations in your DNA, they can shift your lifetime cholesterol exposure substantially.

In one large population study, people in the highest 1 percent of the LDL polygenic score had an average LDL of 4.75 mmol/L, while those in the lowest 1 percent averaged 2.49 mmol/L. That is nearly a two-fold difference written into the genome before anyone ever ate a meal or filled a prescription. Across general populations, this type of score explains roughly 13.8 percent of all variation in measured LDL cholesterol.

This is an emerging clinical tool. There is no universally agreed cutpoint that defines a high score, and laboratories use different SNP (single nucleotide polymorphism) panels, from as few as six variants to several hundred. Treat your result as one piece of a risk picture, not a verdict.

Heart Attack and Coronary Disease Risk

The most important reason to know your score is what it says about heart disease. Higher polygenic scores translate into higher odds of coronary artery disease, and the relationship is proportional to how much the score raises your LDL.

In a Finnish population study, people in the top 5 percent of the LDL polygenic score had about 36 percent higher coronary artery disease odds than those below that threshold. In a Romanian cohort, individuals above the 90th percentile of the score were roughly three times as likely to have premature coronary heart disease. A Danish population analysis found that people in the top 1 percent of the score had nearly twice the risk of ischemic heart disease (odds ratio 1.83) compared to the middle of the distribution.

What this means for you: a high polygenic score nudges your absolute lifetime heart attack risk upward in a way that no single LDL reading can convey. It hints that your body has been pushing more cholesterol into your arteries for decades, even if your current lab numbers look only mildly elevated.

Familial Hypercholesterolemia Without the Single Mutation

For people clinically diagnosed with familial hypercholesterolemia, a single rare mutation is found in only about 20 to 40 percent of cases. The rest have what is called polygenic hypercholesterolemia. One study estimated that the hypercholesterolemia in 88 percent of mutation-negative familial hypercholesterolemia patients is likely polygenic. Combining LDL and lipoprotein(a) polygenic scores has been shown to explain the genetic cause in roughly 26.3 percent of the remaining non-monogenic patients.

If you have very high LDL and a strong family history but standard genetic testing for familial hypercholesterolemia came back negative, a polygenic score can fill in part of the missing picture. It does not replace single-gene testing, but it can clarify whether your high cholesterol is genetically driven by many small contributors rather than one large one.

Reconciling the Apparent Paradox

You will see two findings that seem to clash. People with a known single-mutation familial hypercholesterolemia almost always face higher cardiovascular risk than people with the same LDL level driven by a high polygenic score. In one analysis, monogenic familial hypercholesterolemia carried a hazard ratio of about 1.93 for cardiovascular disease while polygenic hypercholesterolemia carried about 1.26 at similar LDL levels.

This is not a contradiction. The polygenic score reflects a slower, more diffuse genetic push on cholesterol over your lifetime, while a single high-impact mutation acts like a stronger lifelong force on the same pathway. A high polygenic score is meaningful, but it does not carry the same weight as a confirmed monogenic mutation. Knowing which one you have changes how aggressive your prevention strategy should be.

How Treatment Response May Differ

Genetics also seem to shape how well cholesterol-lowering drugs work. In one analysis, people with polygenic hypercholesterolemia showed a 55.4 percent reduction in LDL after rosuvastatin treatment, compared with 45.9 percent in those with monogenic familial hypercholesterolemia. This suggests that knowing your genetic background may help predict whether you will reach LDL goals on standard statin therapy or whether you may need more aggressive combination treatment.

Tracking Your Trend

Here is where this test is different from every other lab in your file. Your polygenic risk score does not change. Your DNA is the same at age 25 and age 65. Retesting it serves no purpose. You only need to know it once.

What you should track over time is everything downstream: your LDL, ApoB (apolipoprotein B), lipoprotein(a), and inflammatory markers. If your score is high, those numbers deserve more frequent attention, ideally annually, and any changes you make to diet, exercise, or medication should be confirmed with a follow-up lipid panel three to six months later. The polygenic score sets the backdrop. The other tests tell you what is happening right now.

What Out-of-Pattern Results Should Make You Do

A high polygenic score, especially in the top decile, deserves a workup, not a panic. Pair the result with an ApoB measurement to see how many cholesterol-carrying particles are actually circulating, a lipoprotein(a) test to capture an inherited risk factor that runs along a different track, and a high-sensitivity CRP (C-reactive protein) to gauge background inflammation.

If your score is high and your LDL is borderline, consider whether you have started lifelong LDL exposure earlier than your current age and lab would suggest. This is the scenario where a lipidologist or preventive cardiologist becomes useful. If your score is high and your LDL is already elevated, the case for earlier and more intensive lipid-lowering therapy strengthens. A coronary calcium score or CT angiogram may also help translate genetic risk into a concrete picture of what is happening in your arteries today.

When Results Can Be Misleading

This test has fewer day-to-day confounders than typical blood tests because your genome does not fluctuate. But interpretation can still mislead you in several ways.

• Ancestry mismatch: most polygenic scores were built using genetic data from people of European descent. Their accuracy is lower in people of African, East Asian, South Asian, or Hispanic ancestry, and your score may underestimate or overestimate your true genetic risk if you do not match the reference population.
• Percentile misreading: a percentile rank is not the same as your absolute risk. A score in the 95th percentile means your genetic push is higher than 95 percent of the reference group, not that your chance of a heart attack is 95 percent. Both patients and clinicians have been documented misinterpreting these numbers.
• Confusion with current cholesterol: a high score does not mean your current LDL is high, and a low score does not protect you if your LDL is elevated today. The two measurements answer different questions.
• Confusion with familial hypercholesterolemia testing: a high polygenic score is not the same as having a familial hypercholesterolemia mutation. You may need both tests to fully characterize your genetic risk.